{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:54:12Z","timestamp":1774655652965,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"DOI":"10.7759\/cureus.106002","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:08:49Z","timestamp":1774652929000},"source":"Crossref","is-referenced-by-count":0,"title":["Early Relapse Frequency as a Potential Predictor of Generalization in Ocular Myasthenia Gravis: A Case Report"],"prefix":"10.7759","author":[{"given":"Jun","family":"Terai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Matsubayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misako","family":"Furuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.90a.22017","article-title":"Myasthenia gravis: frequently asked questions","volume":"90","author":"Morren JA","year":"2023","unstructured":"Morren JA, Li Y. Myasthenia gravis: frequently asked questions. Cleve Clin J Med. 2023, 90:103-13. 10.3949\/ccjm.90a.22017","journal-title":"Cleve Clin J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005081.pub3","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"12","author":"Benatar M","year":"2012","unstructured":"Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012, 12:CD005081. 10.1002\/14651858.CD005081.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S389629","article-title":"Ocular myasthenia gravis: a current overview","volume":"15","author":"Behbehani R","year":"2023","unstructured":"Behbehani R. Ocular myasthenia gravis: a current overview. Eye Brain. 2023, 15:1-13. 10.2147\/EB.S389629","journal-title":"Eye Brain"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa K","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, et al.. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve. 2017, 55:794-801. 10.1002\/mus.25397","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb JP","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014, 175:408-18. 10.1111\/cei.12217","journal-title":"Clin Exp Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2018301","article-title":"Treatment of ocular myasthenia gravis","volume":"7","author":"Cornblath WT","year":"2018","unstructured":"Cornblath WT. Treatment of ocular myasthenia gravis. Asia Pac J Ophthalmol. 2018, 7:257-9. 10.22608\/APO.2018301","journal-title":"Asia Pac J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.36185\/2532-1900-038","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer F","year":"2020","unstructured":"Deymeer F. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol. 2020, 39:345-52. 10.36185\/2532-1900-038","journal-title":"Acta Myol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe GI","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999, 52:1487-9. 10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn RJ","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998, 841:769-72. 10.1111\/j.1749-6632.1998.tb11015.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang L","year":"2017","unstructured":"Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017, 17:77. 10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al.. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021, 96:114-22. 10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty E","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS\/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014, 21:687-93. 10.1111\/ene.12359","journal-title":"Eur J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.10.014","article-title":"Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?","volume":"217","author":"Kupersmith MJ","year":"2004","unstructured":"Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?. J Neurol Sci. 2004, 217:123-4. 10.1016\/j.jns.2003.10.014","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1416202551","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome: an overview","volume":"76","author":"Murai H","year":"2024","unstructured":"Murai H. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome: an overview. Brain Nerve. 2024, 76:7-12. 10.11477\/mf.1416202551","journal-title":"Brain Nerve"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli A","year":"2000","unstructured":"Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000, 48:1442-8. 10.1111\/j.1532-5415.2000.tb02635.x","journal-title":"J Am Geriatr Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine BM","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006, 116:2843-54. 10.1172\/JCI29894","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal AT","year":"2014","unstructured":"Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS One. 2014, 9:e114060. 10.1371\/journal.pone.0114060","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1506845","article-title":"Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in myasthenia gravis","volume":"15","author":"Luo L","year":"2024","unstructured":"Luo L, Zhu X, Wen C, et al.. Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in myasthenia gravis. Front Neurol. 2024, 15:1506845. 10.3389\/fneur.2024.1506845","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients","volume":"11","author":"Wang L","year":"2021","unstructured":"Wang L, Wang S, Yang H, et al.. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav. 2021, 11:e02203. 10.1002\/brb3.2203","journal-title":"Brain Behav"},{"key":"ref20","article-title":"Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis","volume":"59","author":"Aurangzeb S","year":"2009","unstructured":"Aurangzeb S, Tariq M, Irshad M, Badshah M, Khan RS. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J Pak Med Assoc. 2009, 59:289-92.","journal-title":"J Pak Med Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: Is it different?","volume":"1132","author":"Aarli JA","year":"2008","unstructured":"Aarli JA. Myasthenia gravis in the elderly: Is it different?. Ann N Y Acad Sci. 2008, 1132:238-43. 10.1196\/annals.1405.040","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar M","year":"2006","unstructured":"Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006, 16:459-67. 10.1016\/j.nmd.2006.05.006","journal-title":"Neuromuscul Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie GO","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, et al.. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010, 17:893-902. 10.1111\/j.1468-1331.2010.03019.x","journal-title":"Eur J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa Y","year":"2019","unstructured":"Ozawa Y, Uzawa A, Kanai T, et al.. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. J Neurol Sci. 2019, 402:12-5. 10.1016\/j.jns.2019.05.003","journal-title":"J Neurol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01335-3","article-title":"Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis","volume":"20","author":"Uzawa A","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S, et al.. Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis. Neurotherapeutics. 2023, 20:518-23. 10.1007\/s13311-022-01335-3","journal-title":"Neurotherapeutics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419876521","article-title":"Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis","volume":"12","author":"Li M","year":"2019","unstructured":"Li M, Ge F, Guo R, et al.. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2019, 12:10.1177\/1756286419876521","journal-title":"Ther Adv Neurol Disord"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80172","article-title":"Effectiveness of immunosuppressive therapy in preventing the progression of ocular myasthenia gravis to generalized myasthenia gravis: a systematic review and meta-analysis","volume":"17","author":"Nall S","year":"2025","unstructured":"Nall S, Majeed J, Ahmed Mohsen Alrashidi A, et al.. Effectiveness of immunosuppressive therapy in preventing the progression of ocular myasthenia gravis to generalized myasthenia gravis: a systematic review and meta-analysis. Cureus. 2025, 17:e80172. 10.7759\/cureus.80172","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469193-early-relapse-frequency-as-a-potential-predictor-of-generalization-in-ocular-myasthenia-gravis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:08:50Z","timestamp":1774652930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469193-early-relapse-frequency-as-a-potential-predictor-of-generalization-in-ocular-myasthenia-gravis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.106002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}